Sponsor
University of Nebraska
Clinical research sponsor
Clinical trials
60 shownAbi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate CancerNCT07237269 · lead sponsor · 2026-10-15
RECRUITINGPSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate CancerNCT07234981 · lead sponsor · 2026-03-31
RECRUITINGAttention and Eye Movement in Parkinson's DiseaseNCT06899022 · lead sponsor · 2025-09-22
RECRUITINGERAS Protocols in Breast Conserving SurgeryNCT06938581 · lead sponsor · 2025-07-11
RECRUITINGSCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial DiseaseNCT06480786 · lead sponsor · 2024-12-18
RECRUITINGThe Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)NCT06524856 · lead sponsor · 2024-10-01
RECRUITINGHEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection FractionNCT05784753 · lead sponsor · 2023-11-20
RECRUITINGHigh-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate CancerNCT05754580 · lead sponsor · 2023-08-29
RECRUITINGAdaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)NCT05070013 · lead sponsor · 2021-11-18
RECRUITINGNovel DBS Stimulation Patterns for Treatment of Parkinson's DiseaseNCT04799470 · lead sponsor · 2021-05-10
RECRUITINGBlood Markers of Early Pancreas CancerNCT03568630 · lead sponsor · 2018-07-26
RECRUITINGEarly Rheumatoid Arthritis Lung Disease StudyNCT03192267 · lead sponsor · 2017-03-31
RECRUITINGIntegrated Cancer Repository for Cancer ResearchNCT02012699 · lead sponsor · 2013-11-01
RECRUITINGTreatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseNCT03414502 · lead sponsor · 2007-12-10
RECRUITINGDe-escalation of Axillary Dissection for Node-positive Breast CancerNCT07856160 · lead sponsor · 2026-10-15
NOT_YET_RECRUITINGCommunity Support and Mobile Apps to Help Black Women Control High Blood Pressure After PregnancyNCT07606027 · lead sponsor · 2026-10-01
NOT_YET_RECRUITINGModulating Locomotor-Respiratory Coupling Through Adaptive Exoskeleton Assistance in Patients With COPDNCT07703527 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGWhole Versus Partial Gland Boost During Prostate SBRTNCT07574489 · lead sponsor · 2026-07-25
NOT_YET_RECRUITINGCOQ10 and Vitamin E for Off-Target Radiation ToxicityNCT07668284 · lead sponsor · 2026-07-01
NOT_YET_RECRUITINGFeasibility and Performance of Continuous Glucose Monitoring to Guide Computerized Insulin Infusion Therapy in Non-ICU Patients Receiving Corticosteroid Therapy and Specialized NutritionNCT07194642 · lead sponsor · 2026-05-30
NOT_YET_RECRUITINGTrabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1NCT06579196 · lead sponsor · 2025-05-12
ACTIVE_NOT_RECRUITINGTheophylline Nasal Spray for PD-Related Hyposmia and AnosmiaNCT06498687 · lead sponsor · 2025-04-01
WITHDRAWNIMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan AreasNCT06451341 · lead sponsor · 2024-07-01
ACTIVE_NOT_RECRUITINGAssessing Continuous Glucose Monitor Use in Underserved Primary Care PatientsNCT05766488 · lead sponsor · 2023-07-24
ENROLLING_BY_INVITATIONThe Lymphoid Tissue Pharmacology of Antiretroviral DrugsNCT02707926 · lead sponsor · 2023-03-25
WITHDRAWNBiomarker Validation Following Sargramostim Treatment in Parkinson's DiseaseNCT05677633 · lead sponsor · 2023-01-19
COMPLETEDEffect of Computerized Cognitive Training in Persons With MSNCT05345288 · lead sponsor · 2022-06-28
COMPLETEDRural HEART Camp Connect: A Feasibility StudyNCT05647759 · lead sponsor · 2022-06-01
COMPLETEDHigh-intensity Exercise After TreatmentNCT04950010 · lead sponsor · 2022-03-28
TERMINATEDHEART Camp Connect: A Feasibility StudyNCT05985395 · lead sponsor · 2022-03-28
TERMINATEDClinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyNCT05069038 · lead sponsor · 2022-03-02
ACTIVE_NOT_RECRUITINGStrength, Aging, and Memory in Prostate CancerNCT04852224 · lead sponsor · 2021-10-01
COMPLETEDEvaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart TransplantationNCT05038943 · lead sponsor · 2021-09-15
COMPLETEDSafety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabNCT04748419 · lead sponsor · 2021-07-15
TERMINATEDPackaging Building Healthy Families for Community ImplementationNCT04719442 · lead sponsor · 2021-06-01
WITHDRAWNFamily Connections: Cultural Adaptation and Feasibility Testing for Rural Latino CommunitiesNCT04731506 · lead sponsor · 2021-06-01
TERMINATEDThe Patterns of Activity and Cognition During Treatment (PACT) StudyNCT04562987 · lead sponsor · 2021-01-15
COMPLETEDSafety and Effectiveness of NRP for DCD Heart TransplantationNCT04626284 · lead sponsor · 2021-01-03
COMPLETEDAdaptive Neurostimulation to Restore Sleep in Parkinson's DiseaseNCT04620551 · lead sponsor · 2020-10-21
COMPLETEDA Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCNCT03963414 · lead sponsor · 2020-09-25
TERMINATEDLongitudinal Analysis of Gait Variability to Predict Falls in Parkinson's DiseaseNCT04339543 · lead sponsor · 2020-02-28
TERMINATEDValidity of Physical Activity Questionnaires in Persons Pursuing Bariatric SurgeryNCT03981978 · lead sponsor · 2020-01-01
COMPLETEDEffects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) PatientsNCT03514875 · lead sponsor · 2019-11-11
WITHDRAWNStudy on Physical Activity's Relationship With Cancer and CognitionNCT03980626 · lead sponsor · 2019-09-30
COMPLETEDSustaining the Reach of a Scalable Weight Loss Intervention Through Financial IncentivesNCT04225234 · lead sponsor · 2019-08-20
TERMINATEDUnderstanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom ExperienceNCT03724331 · lead sponsor · 2019-06-04
COMPLETEDMeasurement of Beta Cell Death in Individuals With Cystic FibrosisNCT03713437 · lead sponsor · 2019-04-04
COMPLETEDExergaming in Advanced HF With Multiple Chronic Conditions Prior to LVAD Implantation or Heart TransplantNCT03580759 · lead sponsor · 2019-03-01
COMPLETEDBiomarker Assessments of Leukine During Treatment of Parkinson's DiseaseNCT03790670 · lead sponsor · 2019-01-30
COMPLETEDExamining Reach and Implementation of an Evidence-based Weight Loss Program in Rural Primary CareNCT03690557 · lead sponsor · 2018-10-24
COMPLETEDLoop Duodenal Switch: Outcomes at One YearNCT03206736 · lead sponsor · 2018-08-09
TERMINATEDFacilitating Oncology Patient-Clinician Communication Via E-health InnovationsNCT03442127 · lead sponsor · 2018-01-31
COMPLETEDA Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender WomenNCT03270969 · lead sponsor · 2018-01-05
COMPLETEDRole of Circulating Innate Lymphoid Cells in Allergic DisordersNCT03069495 · lead sponsor · 2017-08-21
TERMINATEDReducing Distress and Depressive-symptoms in Rural WomenNCT03465813 · lead sponsor · 2017-07-19
COMPLETEDAssessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors ClinicNCT03431831 · lead sponsor · 2017-07-01
COMPLETEDFactors Affecting Aqueous Humor Outflow Facility in Patients with UveitisNCT02613442 · lead sponsor · 2017-04-13
WITHDRAWNPharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected WomenNCT02722421 · lead sponsor · 2017-04-06
COMPLETEDBest Incision Site for Obese Patients - Low Versus High TransverseNCT03041220 · lead sponsor · 2016-12-01
WITHDRAWNRanibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 StudyNCT02511067 · lead sponsor · 2016-10-01
WITHDRAWNSponsor roles
lead sponsor133
collaborator37
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.